Open AccessRole of angiotensin-converting enzyme inhibitors in reducing cardiovascular and cerebral complications in chronic kidney disease: focus perindopril
Author(s) -
И. Т. Муркамилов
Publication year - 2021
Publication title -
klinicist
Language(s) - English
Resource type - Journals
eISSN - 2412-8775
pISSN - 1818-8338
DOI - 10.17650/1818-8338-2020-14-3-4-k601
Subject(s) - perindopril , kidney disease , medicine , kidney , angiotensin converting enzyme , dialysis , renin–angiotensin system , disease , pharmacology , blood pressure
In the development of renocardial relationships in chronic kidney disease, an important role is given to the activation of the renin-angiotensin-aldosterone system (RAAS), as the main component of the progression and development of cardiovascular complications..The presented review is devoted to the analysis of modern scientific data on the effect of high RAAS activity in chronic kidney disease on the course and prognosis of cardiovascular complications, as well as the protective capabilities of angiotensin-converting enzyme inhibitors, in particular perindopril. The results of scientific research on the role of the RAAS in the progression of chronic kidney disease are summarized. Data on chronic kidney disease as a risk factor for cardiovascular and cerebral complications are presented. Attention is focused on the possibilities of prolonging the pre-dialysis period of chronic kidney disease when using angiotensin-converting enzyme inhibitors. The role of perindopril as a lipophilic angiotensin-converting enzyme inhibitor with a high affinity for tissue RAAS was emphasized in reducing cardiovascular and cerebral risk in chronic kidney disease.